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STEROID AMELIORATION OF IMMUNOGENIC INSULIN-RESISTANT
DIABETES: A PROPOSED MECHANISMt
Among the possible mechanisms of insulin resistant diabetes, binding of
insulin in the intravascular' or interstitial compartments by antibody has
received- considerable investigative attention.' Although adrenal steroid.s
are often helpful in this situation,'evidence that steroid-induced reduction of
insulin antibody is the cause of reduction in insulin requirement remains
equivocal.2"3 Two observations suggest that amelioration of insulin resistance
is not caused by steroid-induced suppression of antibody formation: (a)
insulin requirement often falls quickly, within the first week of treatment,
whereas the half life of gamma globulin is two weeks or more; and (b)
the measured reduction in insulin antibodies does not correspond well to
the change in insulin requirements.2
The present report was stimulated by the admission to Yale-New Haven
H-ospital of a 72-year-old Negro woman in diabetic acidosis, who. required
3,200 units of insulin (Lilly)t to achieve a precarious control of carbo-
hydrate metabolism. After the initial episode, maintenance of' diabetic
control necessitated 350-400 units of insulin daily. On three. separate
occasions this requirement fell to 80-100 units daily within six days after
institution of steroid therapy. Evidence is presented in this report to
demonstrate that: (a) insulin binding was predominately, but not exclu-
sively, by. gamma G globulin; (b) steroi.d treatment did not affect.the half
life of circulating insulin-anti insulin complexes; (c) serum obtained prior
to steroid treatment consistently bound more insulin than did serum
obtained after treatment when compared directly in equilibrium dialyses.
MATERIALS AND METHODS
Serum was obtained at the times specified and tested for its capacity to bind insulin
by the method of Berson, et al.' using Il"l labelled beef insulin with specific activity
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of 4 mc/mg. (Abbott Laboratories) and concentrations of 0.028 mg/ml. This
method depends upon the finding that "free" insulin migrates, on filter paper, in an
electric field, faster than insulin bound to antibody. Radioactive insulin is added to
portions of the patient's serum with increasing amounts of non-radioactive insulin.
Displacement of the "bound" radioactive insulin into the "free" portion by the non-
radioactive insulin is used to calculate insulin binding capacity. Tests were performed
in duplicate and calculated as insulin binding units per liter of serum.
Electrophoresis
Cellulose acetate strips, 10 x 16 mm., were soaked in pH 8.6 veronal buffer and
0.010 ml. of serum containing 2 ,uc/ml. of radioactive insulin (RAI) was placed
in the center of the strip by a calibrated applicator. Electrophoresis at 240 volts and
3 mA. proceeded for two hours at room temperature and strips were dried, stained
with ponceau red, and scanned in a Beckman analytrol. That portion of the strip
containing the electrophoretic pattern was cut into 5 mm. pieces and each piece
placed in a tube; counts were performed in a well-type scintillation counter for
periods sufficient to insure a counting error less than 5 per cent.
Iimmunoelectrophoresis
Immunoelectrophoreses of insulin-serum mixtures were performed by the micro-
method of Scheidegger.' To 0.1 ml. of the patient's serum, 0.01 ml. of the RAI was
added. Following a variable incubation period at 4°C. the mixture was electrophoresed
and developed with rabbit antihuman serum. After washing, drying, and staining with
amido black, the slides were incubated face down on Polaroid type 57 film in the
dark for seven days, and the resulting radioautographs were compared with the
original slide to determine serum binding sites of insulin.
Preparation of rabbit antihuman IgG antiserum
The gamma G (IgG) globulin antigen was prepared from serum of a patient
with multiple myeloma. The serum contained a cryoglobulin which was purified by
precipitating it three times from cold saline. Immunization of rabbits produced only
IgG and kappa light chain antibodies. The latter were absorbed with Bence-Jones
protein obtained from the same patient. Following absorption the antiserum revealed
only one precipitin line when used to develop the immunoelectrophoretic pattern of
normal human serum. Quantitative precipitin tests revealed 260 Ag antibody
nitrogen/ml.
Quantitative precipitation of patient's IgG globulint
Samples of patient's sera were diluted 1: 50 in normal saline and 0.5 ml. added to
1.5 ml. of rabbit antiserum. Precipitates were incubated for 24 hours at 4'C., and
centrifuged at 3,000 g; supernates were routinely precipitated by the addition of
IgG globulin to demonstrate the presence of excess anti-IgG antibodies and thereby
insure the quantitative precipitation of the patient's gamma G globulin.
Equilibrium dialyses
Insulin binding in serum obtained before steroid treatment could be compared
directly with serum after treatment by means of equilibrium dialyses. The absence
of possible shifts of fluid accompanying steroid treatment was evaluated by means
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of hematocrit and serum albumin determinations. All serum samples used in these
experiments were aged for 75 days at 4°C. to destroy endogenous insulin. Two
similar dialysis bags were prepared so that insulin could move into the bags froml
a common surrounding bath and the antibodies of serum samples to be compared
within the bags could not diffuse out into the bath. Although insulin is a smnall
molecule, it tends to aggregate at neutral pH to a molecular size of 34,000 to
42,000; such aggregates do not readily pass through the pores of cellophane dialysis
tubing. Using hydrostatic pressure, suggested by Craig, et al.,6 Visking cellophale
tubing was stretched from 20/32" diameter to 32/32" before it burst. Lengths of
stretched tubing were divided into four portions. Hemoglobin (MW 16,000-64,000)
from laked human type 0 erythrocytes was placed into one portion and dialyzed
to assure ready passage through the pores. Ten Ac of I"' labelled human serum
albumin (Squibb) was placed in a second portion of tubing and dialysed for two
days to ensure that molecules in size equal to or greater than albumin (molecular
weight 67,000) would not diffuse through the pores. Five milliliter samples of the
patient's serum obtained prior to and after corticosteroid therapy were placed in the
remaining portions of the tubing; these were suspended in a bath containing 8-10 ic of
I"81 labelled insulin in one liter of buffered saline at pH 7.0. Dialyses proceeded at
4'C. for five days; the bags were then emptied and the contents counted in a well-
type scintillation counter and adjusted for volume changes. In each experiment a
different dialysis bag was prepared as described; pre- and post-treatment sera were
always compared with portions of the same stretched tubing.
RESULTS
Identity of proteins binding insulin in serumt:
Cellulose acetate electrophoresis of the patient's serum revealed hyper-
globulinemia with 4.9 gm. of globulin per 100 ml. of serum. Migratioln of
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FIG. 1. (Figs. la and lb). Electrophoresis oIn cellulose acetate strips of radioactive
insulin-serum mixtures. Figure la contains noni-diabetic hyperglobulinemic serum and(
RAI. Figure lb contains patient's serum and RAI. Continuous line is plot of protein
concentration; -o-o- represents radioactivity; T is point of application.
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FIG. 2. Immunoelectrophoresis and radioautographs of serum-insulin mixture after
varying times of incubation at 4°C. Slide a, top well-normal + RAI, 30 minute
incubation; a, bottom well-patient's serum + RAI, 30 minute incubation. Slide b,
top well-patient's serum + RAI, 1 hour incubation; b, bottom well-patient's serum
+ RAI, 2 hour incubation. Slide c, top well-patient's serum + RAI, 4 hour incu-
bation; c, bottom well-patient's serum + RAI, 21 hour incubation. Slide d, top well
-patient's serum + RAI, 30 hour incubation; d, bottom well-patient's serum +
RAI, 72 hour incubation.
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RAI added to the serum was associated entirely with the globulin fraction
as shown in Figure lb. A serum from a patient with hyperglobulinemia,
predominantly of the /8 mobility, was similarly processed (Fig. la) and
migration of all radioactivity was considerably faster, appearing on the
anodal side of the origin; no radioactivity appeared associated with gamma
globulin.
A series of immunoelectrophoreses of serum-insulin mixtures were per-
formed after variable periods of incubation of serum with RAI from 30
minutes to 72 hours at 4°C. All immunoelectrophoreses were developed
TABLE 1. SERUM INSULIN BINDING CAPACITY OBTAINED BEFORE
AND DURING STEROID TREATMENT
Day of treatment Binding capacity Mean
U/L U/L
-8 675
-7 810
636
-6 550
-5 490
+5 510
+7 640 587
+9 610
with rabbit antihuman serum, and radioautographs were prepared from the
dried slides. Control serum incubated with RAI for 30 minutes revealed
a blank radioautograph indicating no insulin binding (Fig. 2). A portion of
the IgG precipitin line formed by the patient's serum-insulin mixture,
which had been incubated for 30 minutes prior to immunoelectrophoresis,
was clearly radioactive. With incubation of serum and insulin for one hour
or longer, radioactivity appeared in a second precipitin line; furthermore,
the intensity of the radioactivity of this line appeared to increase with the
length of incubation. The second line was identified as alpha 2 macro-
globulin by means of specific absorbed antiserum* directed against human
alpha 2 macroglobulins.
Effect of steroids on clearance of IgG globulin-bound insulin:
Two weeks after cessation of steroid therapy, the patient was nmaintained
on 400 units of insulin daily, in three divided doses. Two hundred ,uc. of
* Obtained from Hyland Laboratories, Los Angeles, California.
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I13S labelled insulin were injected four hours after the last therapeutic dose.
Serum samples were obtained at intervals, and the gamma globulin quanti-
tatively precipitated by rabbit antiserum specifically directed against the
IgG globulin. Precipitates were washed three times in the cold and counted
in a well-type scintillation counter. Gamma globulin-bound insulin was
plotted as a function of the time (Fig. 3) and disappeared with a half life
of 26 hours. Prednisone (40 mg/day) was reinstituted and after four
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FIG. 3. Effect of steroid treatment oni clearance of gamma-globulin-bound insulin.
days the patient's insulin requirement fell to 50-100 units daily. Ten days
after prednisone therapy was reestablished, clear of 150 /Ac. of injected
radioactive insulin was measured. The half life of gamma G globulin-bound
insulin was 25 hours, clearly indicating that steroid therapy did not alter
the rate of removal of insulin-anti insulin complexes from the circulation.
Insulin binding capacity of serumn before and after steroid treatment:
Insulin binding capacity was measured several times by the method of
Berson, et al. before prednisone therapy was begun and on days 5, 7, and 9
following onset of treatment. Although the mean value after treatment
(Table 1), was consistently lower than before, the differences were not
significant.
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Steroid treatment was then discontinued and the patient was maintained
on three daily doses of crystalline beef insulin. Several serum samples were
obtained at various times during the 6 days before reinstitution of steroids;
these samples were paired as to time of withdrawal with serum obtained
during the 4th to 6th days following onset of treatment to control factors
of diet and insulin administration. Serum pairs were then examined
by equilibrium dialyses in baths containing radioactive insulin. In each
experiment portions of the same stretched dialysis tubing were used in
comparing the previously paired samples. Because individual bags vary in
TABLE 2. BINDING OF RADIOACTIVE INSULIN BY SERUM PAIRS
AFTER EQUILIBRIUM DIALYSES
Time serum obtained Counts per minute bound
(Hours) (CPM)
After last After last Pre-steroid Post-steroid Ratio CPM
Exper. no. insulin meal serum (A) serum (B) A/B
1 14 16 95,595 82,770 1.16
2 4 3.5 42,123 25,875 1.61
3 5 4 35,953 30,735 1.16
4 18 16 92,875 82,808 1.13
5 4 3.5 33,810 28,448 1.15
6 4 3.5 105,200 80,454 1.31
7 4 3.5 98,432 87,005 1.13
pore size, comparison of a pre-steroid serum sample from one dialysis
experiment with a post-steroid sample from another would not be valid.
Pre-steroid serum bound more radioactive insulin than did the post-steroid
serum in each case, as shown in Table 2. The likelihood of chance favoring
greater insulin binding by seven consecutive pre-treatment samples com-
pared to post-treatment samples is less than 1 per cent by the simple
ranking statistic (Y2) .
DISCUSSION
Why the use of steroids reduces the requirement for insulin in certain
cases of insulin resistant diabetes is unknown. If an immune basis is
assumed for insulin resistance where high levels of anti-insulin antibody
are demonstrated, the possible explanations for the paradoxical reduction
of insulin requirements by adrenal steroids include:
1) rapid reduction of antibody levels,
2) delay in removal of insulin antibody complexes by the reticulo-
51
KANTOR, BERKMANYALE JOURNAL OF BIOLOGY AND MEDICINE
endothelial system allowing more time for dissociation of com-
plexes,
3) increase in rate of dissociation of insulin antibody complexes to
provide free insulin.
Previous reports have failed to document a rapid, significant fall in
insulin antibody levels which corresponded to the observed fall in insulin
requirement attending steroid therapy. Data presented above (Table 1)
are similar to earlier investigations where a downward trend in insulin
antibody levels was noted but was not believed to be the basis for the fall
in insulin requirements. Studies of steroid effects upon levels of anti-
bodies of diverse types have revealed suppression of antibody production,"8
but very slow reduction of existing serum antibody levels.9
The second postulated mechanism involves the effect of steroids on the
half life of insulin-antibody complexes in the circulation. Clearance studies
of injected radioactive insulin performed by quantitative precipitation of
insulin-antibody complexes failed to demonstrate a steroid effect. The lhalf
life of gamma G antibody-bound insulin was found to be 25 to 26 hours
before and after prednisone-induced reduction of insulin requirement,
whlich is similar to that reported for clearances of soluble complexes of
other antigen-antibody systems.'0 Indeed, previous studies on clearances of
diverse particles or macromolecular complexes have uniformly failed to
show an impairment of reticuloendothelial function under the influence of
adrenal hormones."
In the course of experiments designed to determine the type of insulin
binding antibodies present in our patient, we noted that prolonged incu-
bation of radioactive insulin-serum mixtures resulted in binding of radio-
activity to alpha 2 macroglobulins in addition to gamma G globulin,
a finding previously reported by Clausen, et al."2 The significance of this
observation is not clear. Berson and Yalow, in an addendum to their paper4
reported changes in insulin molecules produced by x-radiation that resulted
in migration of irradiated insulin with the alpha globulins. Later studies by
these investigators on the behavior of plasma insulin in the ultracentrifuge
and on starch gel electrophoresis failed to demonstrate an insulin binding
protein in normal serum>; they have suggested that self-irradiation of
labelled insulin or radiation-induced alteration of serum protein(s) pro-
duces the alpha 2 bound radioactivity. Others have reported that a signifi-
cant portion of plasma insulin is bound to normal plasma protein" or exists
in a macromolecular compound.5 The present studies do not resolve the
issue of whether insulin is normally bound in plasma, but the apparent
increase in binding as a function of time in hours supports the contention
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that alteration of insulin, or a plasma protein, by radioactivity, is necessary
for binding to occur. With a half life of plasma insulin only 30 minutes in
normal subjects, it would appear that significant plasma protein binding
inz vivo is less likely.'
The results of equilibrium dialyses clearly established that the serum
obtained prior to steroid therapy preferentially bound insulin when com-
pared directly with serum obtained shortly after the onset of treatment.
Equilibrium dialysis measures two aspects of insulin antibody interaction:
the amount of antibody, and its affinity for insulin. Were steroids to affect
the level of a relatively small amount of highly avid antibody, then deter-
miinations of insulin binding capacity by usual means would be little
changed, yet insulin requirement might be affected.
The calculation of insulin binding capacity is made by determining the
amnount of insulin bound to antibody and that remaining free in mixttures
of serum and varying amounts of insulin.' The basis for the calculation
involved is reviewed briefly below:
When insulin (Ag) and antibody (Ab) react, they formii a complex AgAb
(1) Ag + Ab = AgAb
which may be expressed
(2) K AgAb
[Ag] [Abe] where Ab11 is unbound antibody.
The concentration of the bound insulin B is equal to the concentration of
the complex AgAb. Equation (2) may be written
B
(3) K- where F is concentration of free insulin.
F(Abu)
Transposing
B
(4) K(Abu) -
F
Whereas unbound antibody is equal to the total less the bound protein,
and may be written
(5) Abu =Abt -B
Then, from equation (4) and (5)
B
(6) K(Abt - B) = -
F
B
When - = 0, then K(Abt -B) =0; dividing by K yields Abt - B =0; F
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Abt= B. When observed ratios of bound over free insulin are plotted
against bound insulin as shown in Figure 4, and the plot is extrapolated
to 0, the value of bound insulin is equal to the insulin binding capacity of
the serum. However, although the association constant K may affect the
B
ratios at various insulin concentrations, the calculation of insulin binding F
capacity is made with a vast excess of free insulin, i.e., infinitely low
B
- ratios, at which the value of K does not enter the calculation.
F
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FIG. 4. Example of plot of bound insulin vs. bound/free insulin extrapolated to 0 to
calculate insulin binding capacity.
The amount of antigen bound by an antibody is dependent upon the
concentration of the reactants, and the association constant (K) of the
reaction (equation 2). This constant, K, defines the avidity of the antibody
for antigen and may vary from one antibody to another over a range of
several orders of magnitude. It is clear that similar concentrations of two
antibodies, directed against the same antigen, may bind antigen in amounts
as dissimilar as their association constants, viz. 103 vs. 108. Since the
immune response to a protein such as insulin is always heterogeneous,
a single serum will contain many types of antibodies of widely varying
avidities; evaluation of the association constant of such antibodies is an
average of all the association constants. Previous studies have investigated
the binding constants (K) of antibodies obtained from patients without
insulin resistance as well as those from insulin-resistant diabetics."7 The
results indicated a higher average association constant of the antibodies in
sera from non-resistant diabetic patients. Since the insulin binding capacities
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of resistant sera were several times greater than those of the non-resistant
sera, the bulk of antibody in the resistant sera is likely to be of relatively
low avidity.
Based on studies in this patient, a postulated mechanism for steroid
amelioration of insulin resistance involves: 1) rapid decline or cessation
of antib-ody production by the steroids; 2) continued administration of
insulin to maintain a patient free of ketoacidosis, resulting in selective
formation of insulin complexes with high avidity antibody; these complexes
are removed with a half life of about one day. Within three to four days
avid antibody, consisting of only a small portion of the insulin binding
antibodies, is reduced tenfold and, although insulin binding capacity is
little changed, insulin requirement falls.
Such a postulate may be tested in vitro by measuring average avidity of
sera before and after steroid treatment, and in vivo by testing relative
potency of pre- and post-treatment sera (adjusted to equal insulin binding
capacities) in suitable biological systems.
SUMMARY
Insulin antibodies of the gamma G type were found in a patieint admitted
with insulin resistant diabetes. Steroid therapy achieved considerable
reduction in insulin requirement; however, there was little reduction in
the insulin binding capacity of the patient's serum samples when measured
by the displacements of radioactive insulin by non-radioactive insulin. The
half lives of circulating insulin-antibody complexes were unaffected by
treatment. Post-treatment sera consistently bound less insulin when com-
pared directly to pre-treatment samples in equilibrium dialyses. A posu-
lated mechanism for the steroid effect in reduction of instulin requiremnents
is presented.
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